Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Cancer

Date Submitted: Apr 4, 2018
Open Peer Review Period: Apr 5, 2018 - May 3, 2018
Date Accepted: Jun 19, 2018
(closed for review but you can still tweet)

The final, peer-reviewed published version of this preprint can be found here:

Exploring the Most Visible German Websites on Melanoma Immunotherapy: A Web-Based Analysis

Brütting J, Steeb T, Reinhardt L, Berking C, Meier F

Exploring the Most Visible German Websites on Melanoma Immunotherapy: A Web-Based Analysis

JMIR Cancer 2018;4(2):e10676

DOI: 10.2196/10676

PMID: 30545808

PMCID: 6315239

Exploring Most Visible German Websites on Melanoma Immunotherapy: A Web-Based Analysis

  • Julia Brütting; 
  • Theresa Steeb; 
  • Lydia Reinhardt; 
  • Carola Berking; 
  • Friedegund Meier

ABSTRACT

Background:

Patients diagnosed with melanoma frequently search the internet for treatment information, including novel and complex immunotherapy. However, health literacy is limited among half of the German population, and no assessment of websites on melanoma treatment has been performed so far.

Objective:

The aim of this study was to identify and assess the most visible websites in German language on melanoma immunotherapy.

Methods:

In accordance with the common Web-based information-seeking behavior of patients with cancer, the first 20 hits on Google, Yahoo, and Bing were searched for combinations of German synonyms for “melanoma” and “immunotherapy” in July 2017. Websites that met our predefined eligibility criteria were considered for assessment. Three reviewers independently assessed their quality by using the established DISCERN tool and by checking the presence of quality certification. Usability and reliability were evaluated by the LIDA tool and understandability by the Patient Education Materials Assessment Tool (PEMAT). The Flesch Reading Ease Score (FRES) was calculated to estimate the readability. The ALEXA and SISTRIX tools were used to investigate the websites’ popularity and visibility. The interrater agreement was determined by calculating Cronbach alpha. Subgroup differences were identified by t test, U test, or one-way analysis of variance.

Results:

Of 480 hits, 45 single websites from 30 domains were assessed. Only 2 website domains displayed a German quality certification. The average assessment scores, mean (SD), were as follows: DISCERN, 48 (7.6); LIDA (usability), 40 (2.0); LIDA (reliability), 10 (1.6); PEMAT, 69% (16%); and FRES, 17 (14), indicating mediocre quality, good usability, and understandability but low reliability and an even very low readability of the included individual websites. SISTRIX scores ranged from 0 to 6872 and ALEXA scores ranged from 17 to 192,675, indicating heterogeneity of the visibility and popularity of German website domains providing information on melanoma immunotherapy.

Conclusions:

Optimization of the most accessible German websites on melanoma immunotherapy is desirable. Especially, simplification of the readability of information and further adaption to reliability criteria are required to support the education of patients with melanoma and laypersons, and to enhance transparency.


 Citation

Please cite as:

Brütting J, Steeb T, Reinhardt L, Berking C, Meier F

Exploring the Most Visible German Websites on Melanoma Immunotherapy: A Web-Based Analysis

JMIR Cancer 2018;4(2):e10676

DOI: 10.2196/10676

PMID: 30545808

PMCID: 6315239

Per the author's request the PDF is not available.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.